ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 214 filers reported holding ROYALTY PHARMA PLC in Q1 2021. The put-call ratio across all filers is 1.03 and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,390,113 | -11.6% | 309,142 | +0.2% | 0.02% | -4.8% |
| Q2 2023 | $9,485,810 | -13.0% | 308,582 | +2.0% | 0.02% | -16.0% |
| Q1 2023 | $10,899,435 | -8.4% | 302,510 | +0.4% | 0.02% | -13.8% |
| Q4 2022 | $11,903,819 | +2.0% | 301,210 | +3.7% | 0.03% | -3.3% |
| Q3 2022 | $11,673,000 | -4.4% | 290,530 | 0.0% | 0.03% | 0.0% |
| Q2 2022 | $12,214,000 | +10.3% | 290,530 | +2.2% | 0.03% | +42.9% |
| Q1 2022 | $11,074,000 | -0.6% | 284,235 | +1.7% | 0.02% | +5.0% |
| Q4 2021 | $11,137,000 | +25.5% | 279,463 | +13.8% | 0.02% | +17.6% |
| Q3 2021 | $8,873,000 | -11.1% | 245,520 | +0.8% | 0.02% | -10.5% |
| Q2 2021 | $9,983,000 | +8.7% | 243,550 | +15.7% | 0.02% | +5.6% |
| Q1 2021 | $9,185,000 | +634.2% | 210,575 | +742.3% | 0.02% | +500.0% |
| Q4 2020 | $1,251,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |